Skip to main content
Clinical Trials/NCT03009253
NCT03009253UnknownNot Applicable

Translational Research on Locally Advanced Pancreatic Adenocarcinoma

Cancer Institute and Hospital, Chinese Academy of Medical Sciences1 site in 1 country40 target enrollmentStarted: July 2015Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Enrollment
40
Locations
1
Primary Endpoint
translational resection rate

Study Overview

Brief Summary

The purpose of this study is to find the best neoadjuvant therapy for pancreatic adenocarcinoma.

Detailed Description

The trial is prepared to be registered on the clinicaltrail.gov. Quality assurance plan: Every participant is enrolled or excluded by two practiced investigators. And two investigators participated in all steps of the trail, including the record of the data, and the investigators will compare the data. If the data is consistent,the investigators would record the data; if not, the data would be checked and decided by the two investigators. All the steps and data are site monitored and audited by the workers of research and financial department of National Cancer Center/ Cancer Hospital, Chinese Academy of Medical Sciences.

Data check: The investigators compare data entered into the registry against predefined rules for range or consistency with other data fields in the registry.Source data verification to assess the accuracy, completeness, or representativeness of registry data by comparing the data to external data sources, including medical records and electronic case report forms.

Data dictionary that contains detailed descriptions of each variable used by the registry,including the source of the variable, coding information, and normal ranges if relevant.Standard Operating Procedures to address registry operations and analysis activities,such as participants recruitment, data collection, data management, data analysis,reporting for adverse events, and change management. All registry operations would be done according to specific steps, and by two practiced investigators.

Sample size assessment to specify the number of participants or participant years necessary to demonstrate an effect. According to the formula to differ advantages and disadvantages, the investigators need at least 80 participants to take part in the trail.

The investigators can recruit about 20 participants every year according to previous experiences, so the investigators should recruit at least for two years.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Single (Outcomes Assessor)

Eligibility Criteria

Ages
18 Years to 70 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • have cytologic or pathological proof of pancreatic adenocarcinoma without surgery contraindication score of ECOG is between 0 and 1 evaluation of CT is unresectable

Exclusion Criteria

  • metastatic pancreatc adenocarcinoma malignant tumors history allergic to 5-FU have difficulty in swallowing joined other clinical trails cardiac and renal disease active infection

Outcomes

Primary Outcomes

translational resection rate

Time Frame: half a year

Secondary Outcomes

  • Local control rate(2 years)
  • progression-free survival(2 years)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Chengfeng Wang

Director of department of pancreatic and gastric surgery

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Study Sites (1)

Loading locations...

Similar Trials